



**SOLVE
ON.**

Incyte Pledges Support to Vitiligo Community through Expansion of Ingenuity Award Program

WILMINGTON, Del. – June 25, 2022 – Incyte is proud to join the vitiligo community to recognize World Vitiligo Day and announce the expansion of the Incyte Ingenuity Awards. The program aims to foster innovative solutions addressing specific needs of the vitiligo community by funding two creative ideas, one to receive up to \$35,000 and the other up to \$100,000.

Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. It affects more than 1.5 million people in the United States and can occur at any age, although many patients with vitiligo will experience initial symptoms before the age of 30.

“At Incyte, we are committed to creating and fostering community-focused programs dedicated to improving the lives of patients, including people with vitiligo, a chronic autoimmune disease that can have a significant impact,” said Todd Edwards, Group Vice President, Business Unit Head, Inflammation and Autoimmunity, Incyte. “Through the Incyte Ingenuity Awards in vitiligo, we hope to spark creativity and innovation that will result in impactful and actionable solutions for the community.”

Submissions for the awards are welcomed from non-profit 501(c)(3), patient, policy and caregiver organizations, as well as healthcare providers and mid-level/junior faculty of healthcare organizations who apply on behalf of their organization. Individuals or other companies interested in applying must partner with either a non-profit organization or a healthcare facility (i.e., hospitals, academic research centers, etc.) to be eligible.

Submissions for the 2022 Incyte Ingenuity Awards in vitiligo are now open and applications are due by October 31, 2022. All applications will be reviewed and evaluated by an independent judging panel made up by members of the vitiligo community. Three semi-finalists will be selected by the judging panel per award to move on to the second and final round of judging. The two award recipients will be announced in March 2023.

“Vitiligo is often overlooked as a cosmetic issue, but for those of us living with vitiligo, we know that it can have a profound impact on daily life,” said Erika Page, founder and editor of *Living Dappled*, a blog and community for women with vitiligo. “I am honored to be serving my community as one of the inaugural judges for these awards, and I look forward to seeing how the proposals submitted may help address specific needs among people living with vitiligo.”

To learn more about the eligibility criteria, the application process and how to submit an application, visit incyteingenuityawards.com/vitiligo.

About Vitiligo

Vitiligo is a chronic autoimmune condition affecting more than 1.5 million people in the United States¹⁻⁴. It occurs when a person's immune system attacks and destroys the pigment-producing cells, also known as melanocytes⁵. This results in skin depigmentation in the form of white patches on the face and body⁶. Vitiligo can occur at any age, although many will experience initial symptoms before the age 30⁷.

About Incyte Dermatology

Incyte's science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company's research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for additional immune-mediated dermatologic conditions with a high unmet medical need, including hidradenitis suppurativa. To learn more, visit the [Dermatology section of Incyte.com](#).

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](#) and follow [@Incyte](#).

#

Contacts:

Media

Jenifer Antonacci

+1 302 498 7036

jantonacci@incyte.com

Erica Cech

+1 302 274 4324

ecech@incyte.com

1. Bergqvist C, Ezzedine K. Vitiligo: A Review. *Dermatology*. 2020;236:571-592. doi: 10.1159/000506103.
2. Krüger C, Schallreuter KU. *Int J Dermatol*. 2012;51:1206-1212.
3. Harris JE, et al. AAD 2020. Poster 17755.
4. Harris JE, et al. MDD 2020.
5. Bowcock AM, Fernandez-Vina M. Targeting skin: vitiligo and autoimmunity. *J Invest Dermatol*. 2012; 132:13-15.
6. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Vitiligo. <https://www.niams.nih.gov/health-topics/vitiligo>. Accessed March 16, 2022.
7. Frisoli M, Essien K, Harris JE, et al. Vitiligo: mechanisms of pathogenesis and treatment. *Annu Rev Immunol*. 2020;38(1):621-648.